| Abciximab versus placebo | |||
| ADMIRAL, 2001 | loading dose 250µg/kg infusion 0.125µg/kg/min for 12h versus | Primary PCI | |
| CADILLAC, 2002 | loading dose 250µg/kg infusion 0.125µg/kg/min for 12h versus | Primary PCI | |
| RAPPORT, 1998 | loading dose 250µg/kg infusion 0.125µg/kg/min for 12h versus | Primary PTCA < | |
| EPIC (with infusion), 1994 | loading dose 250µg/kg infusion 10µg/min for 12h versus | High risk for abrupt closurebitm | |
| EPILOG, 1997 | loading dose 250µg/kg infusion 0.125µg/kg/min (max 10µg) for 12h versus | Elective or urgent PCIe | |
| EPISTENT, 1998 | loading dose 250µg/kg infusion 0.125µg/kg/min for 12h versus | Elective or urgent PCI | |
| CAPTURE, 1997 | loading dose 250µg/kg infusion 10µg/min for 18-24h versus | ||
| ERASER, 1999 | loading dose µg/kg infusion µg/min for h versus | ||
| Petronio, 2002 | loading dose µg/kg infusion µg/min for h versus | ||
| Simoons, 1994 | loading dose µg/kg infusion µg/min for h versus | ||
| Kini, 2001 | loading dose µg/kg infusion µg/min for h versus | ||
| Tamburino, 2002 | loading dose µg/kg infusion µg/min for h versus | ||
| ISAR-2, 2000 | loading dose 250µg/kg infusion 10µg/min for 12h versus | PCI <48 h after MI | |
| aspirin versus placebo | |||
| Taylor (Perth), 1991 | aspirin, 100 mg/day after 2 weeks versus placebo | patients aged less than 70 years without acute infarction undergoing PTCA | double blind Follow-up duration: 6m |
| M-HEART II (aspirin), 1995 | aspirin 325 mg daily versus placebo | patients undergoing PTCA | double blind Follow-up duration: 6m |
| aspirin + dipyridamol versus placebo | |||
| Schwartz (Toronto), 1988 | aspirin 990 + D225 (H) versus placebo | double blind Follow-up duration: 6m Canada | |
| White (aspirin+dipiridamol), 1991 | ticlopidine 500, aspirin 650 + D225 versus | Follow-up duration: 6m | |
| Nye (Dunedin), 1990 | aspirin 300 + D225 versus placebo | NA Follow-up duration: 12m | |
| Mayo-PTCA, 1989 | aspirin 975 + D225 versus | Follow-up duration: 48h | |
| bivalirudin versus heparin + GP2b3a inhibitors | |||
| ACUITY (Stone) (bivalirudin alone), 2006 NCT00093158 | bivalirudin alone versus unfractionated heparin or enoxaparin plus a glycoprotein IIb/IIIa inhibitor | patients with acute coronary syndromes | open Follow-up duration: 30 days |
| HORIZONS-AMI (Stone), 2008 NCT00433966 | Bivalirudin versus Heparin plus GP IIb/IIIa inhibitor | patients with ST-segment elevation myocardial infarction who presented within 12 hours after the onset of symptoms and who were undergoing primary PCI | open Follow-up duration: 30 days 11 countries |
| REPLACE-2, 2003 | bivalirudin, with glycoprotein IIb/IIIa (Gp IIb/IIIa) inhibition on a provisional basis for complications during PCI versus heparin plus planned Gp IIb/IIIa blockade | patients undergoing urgent or elective PCI | double blind Follow-up duration: 30 days 9 countries |
| bivalirudin versus UFH | |||
| ARMYDA BIVALVE, | bivalirudin (0.75 mg/kg bolus followed by 1.75 mg/kg per hour during the procedure) versus unfractionated heparin (75 IU/kg) | patients at high bleeding risk (over 75 years of age, diabetes, reduced renal function) scheduled for PCI | |
| BAT (Bittl), 1995 | bivalirudin immediately before angioplasty. versus heparin immediately before angioplasty | patients undergoing urgent angioplasty for unstable or postinfarction angina | double blind Follow-up duration: hospital stay US |
| ISAR-REACT 3, 2008 NCT00262054 | UFH bolus of 140 U/kg versus bivalirudin (bolus of 0.75 mg/kg, followed by infusion of 1.75 mg/kg/hr) | troponin-negative patients undergoing PCI | double blind Follow-up duration: 30 days (mean) |
| REPLACE-1, 2004 | bivalirudin (0.75 mg/kg bolus, 1.75 mg/kg/h infusion during the procedure versus heparin (70 U/kg initial bolus) adjusted to ACT of 200 to 300s | patients undergoing elective or urgent revascularization | Follow-up duration: hospital stay (48h min) US |
| bivalirudin versus UFH plus tirofiban | |||
| NAPLES (Tavano), 2009 | bivalirudin monotherapy versus unfractionated heparin plus tirofiban | patients with diabetes mellitus undergoing elective percutaneous coronary intervention | open Follow-up duration: 30 days Italy |
| bivalirudin + eptifibatide versus heparin + GP2b3a inhibitors | |||
| Kleiman, 2002 | bivalirudin + eptifibatide versus heparin + eptifibatide | patients who underwent elective percutaneous coronary intervention | open |
| cangrelor versus clopidogrel | |||
| CHAMPION PHOENIX, 2013 NCT01156571 | bolus and infusion of cangrelor followed by 600mg clopidogrel immediately post-infusion versus loading dose of 600 mg or 300 mg of clopidogrel | patients undergoing PCI for stable angina or for acute coronary syndromes, including ST-elevation MI | double-blind Follow-up duration: 48 hours |
| cangrelor up front versus clopidogrel up front | |||
| CHAMPION-PCI, 2009 NCT00305162 | cangrelor up front (cangrelor administered before percutaneous coronary intervention and followed by clopidogrel) versus clopidogrel up front (clopidogrel followed by placebo) | high risk patients requiring PCI | double blind Follow-up duration: 48 h 14 countries |
| cangrelor up front versus delayed clopidogrel | |||
| CHAMPION-PLATFORM, 2009 NCT00385138 | cangrelor up front (cangrelor during PCI followed by 600 mg of clopidogrel) versus delayed clopidogrel (placebo during PCI followed by 600 mg of clopidogrel) | patients with acute coronary syndrome undergoing percutaneous coronary intervention | double blind Follow-up duration: 48 h 18 countries |
| dalteparin versus UFH | |||
| Natarajan (without antiGp2b3a), 2003 | Dalteparin 100 IU/kg bolus versus UFH 100 IU/kg bolus | Elective or urgent PCI | |
| dalteparin versus UFH + anti Gp2b3a | |||
| Natarajan (+ antiGp2b3a), 2003 | Dalteparin 70 IU/kg bolus + GP IIb/IIIa inhibitorse/p versus UFH 70 IU/kg bolus +GPIIb/IIIa inhibitors | ||
| elinogrel versus clopidogrel | |||
| INNOVATE PCI, NCT00751231 | versus | ||
| enoxaparin versus UFH | |||
| ATOLL, 2010 | IV enoxaparin versus UFH | patients undergoing PCI for acute STEMI | open Follow-up duration: 30 days Austria, France, Germany, and US |
| Brieger, | enoxaparin versus unfractionated heparin | patients undergoing percutaneous coronary intervention for ST-segment elevation myocardial infarction (STEMI) | |
| CRUISE, 2003 | Enoxaparin 0.75 mg/kg bolus versus UFH 60 IU/kg bolus, then titrated to ACT > 200 | Urgent or elective PCI | open Follow-up duration: 2,7 +30 days |
| Drozd, 2001 | Enoxaparin 1 mg/kg bolus versus UFH 100 IU/kg bolus | PCI for stable angina | Follow-up duration: 24hrs, 30 days |
| Dudek, 2000 | Enoxaparin 1 mg/kg bolus versus UFH titrated to ACT > 300 | PCI | Follow-up duration: 3à days |
| Dudek b (enox alone), 2000 | Enoxaparin 1 mg/kg bolus versus UFH titrated to ACT > 300 | PTCA complex lesionsCI | |
| Galeote, 2001 | Enoxaparin 0.75 mg/kg bolus versus UFH 70 U/kg bolus, then titrated to ACT > 200 | PTCA patients with stable/unstable angina or AMI | |
| Rabah, 1999 | Enoxaparin 1 mg/kg bolus versus UFH 10,000 IU bolus, then titrated to ACT > 300 | PCI for stable angina | open |
| STEEPLE, 2006 NCT00077844 | enoxaparin (0.5 or 0.75 mg per kilogram of body weight) versus unfractionated heparin (adjusted for activated clotting time) | elective percutaneous coronary intervention. | open |
| enoxaparin+abciximab versus UFH | |||
| Dubek b (+abciximal), 2001 | Enoxaparin 0.75 mg/kg bolus + abciximab versus UFH titrated to ACT > 300 | ||
| Eptifibatide versus placebo | |||
| ESPRIT, 2000 | loading dose 180µg/kg x2 infusion 2µg/min for 18-24h versus | Nonurgent PCI | |
| IMPACT (4h), 1995 | loading dose 90µg/kg infusion 1.0µg/kg/min for 4h versus | Elective PCI | |
| IMPACT-II (0.5µg), 1997 | loading dose 135µg/kg infusion 0.5µg/kg/min for 20-24h versus | Any PCI | |
| Harrington, 1995 | loading dose µg/kg infusion µg/min for h versus | ||
| prasugrel versus clopidogrel | |||
| TRITOM TIMI 38 (PCI subgroup), 2009 | prasugrel (60 mg loading, 10 mg maintenance) versus clopidogrel (300 mg loading, 75 mg maintenance) | subgroup of patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction | |
| JUMBO-TIMI 26, 2005 | Prasugrel 3 doses versus clopidogrel 300mg loading dose followed by 75 mg daily) | patients undergoing elective or urgent percutaneous coronary intervention | double blind Follow-up duration: 30 days |
| reviparin versus UFH | |||
| REDUCE, 1996 | Reviparin 7,000 IU anti-Xa versus UFH 10,000 IU bolus | PTCA with stable/unstable angina | double blind Follow-up duration: 3 days Europe and Canada |
| SCH 530348 versus placebo | |||
| TRA-PCI, 2009 NCT00132912 | SCH 530348 3 doses: 10mg, 20mg and 40mg versus placebo | patients aged 45 years or older and undergoing non-urgent PCI or coronary angiography with planned PCI | double-blind |
| sulotroban versus placebo | |||
| M-HEART II (sulotroban), 1995 | versus placebo | patients undergoing PTCA | double blind Follow-up duration: 6 months |
| ticlopidine versus placebo | |||
| TACT, 1990 | ticlopidine 500, aspirin 650 + D225 versus | Follow-up duration: 6m | |
| White (ticlopidine), 1991 | ticlopidine 500, aspirin 650 + D225 versus placebo | Follow-up duration: 6m | |
| Tirofiban versus placebo | |||
| RESTORE, 1997 | loading dose 10µg/kg infusion 0.15µg/kg/min for 36h versus | PCI <72 h after USA or MI | |
| Kereiakis, 1996 | loading dose µg/kg infusion µg/min for h versus | ||
in first
in second
-
About
-
Browse pathology
|
treatment
-
Site map
-
Credits
Made with in Lyon
-
Contact us
-
Privacy policy
-
